The results provide the rationale for attempts to increase the generation of EETs, possibly by reducing their degradation by sEH, as a new therapeutic approach for the treatment of CHF, particularly of its forms associated with CKD. This evidence concerns the gene EPHX2 and chronic kidney disease.